Leave Your Message

Lactiplantibacillus Plantarum F3-2 Pet Probiotics Powder - China Suppliers & Factory Direct Offer

Deposite: CCTCC M 2020833

Shelf life: 24 months

Storage conditions: Stored at -18℃or lower

Health Benefits

Discover the reliability and excellence of the CCTCC M 2020827, a top-quality product from trusted China suppliers. Our factory ensures the highest standards in manufacturing, providing you with durable and efficient solutions tailored to meet your needs. Choose CCTCC M 2020827 for unparalleled performance and quality, backed by our commitment to exceptional service from our experienced team in China.

    Patent

    ZL202110850565.9
    A strain of lactiplantibacillus plantarum F3-2 and its application

    Applications

    Lacticaseibacillus Paracasei G15 Postbiotics Powder (5)3ar

    Dairy

    Lacticaseibacillus Paracasei G15 Postbiotics Powder (4)oxf

    Food

    Fermented Beveragesmmc

    Fermented Beverages

    Pharmaceuticals1am

    Pharmaceuticals

    Biotechnologyksp

    Biotechnology

    Feed AdditivePetdt0

    Feed Additive/Pet

    Detailed Information

    • Customization: Products customized are acceptable.
    • Potency Options: 10B CFU/g, 50B CFU/g, 100B CFU/g, 200B CFU/g, 300B CFU/g, 400B CFU/g, 500B CFU/g
    • Shelf Life: 24 months
    • Storage Conditions: Stored at -18℃ or below

    Academic Research

    Lactobacillus plantarum F3-2 in combination with mannan oligosaccharide improves obesity in mice by inhibiting PPARγ through up-regulation of SCFAs

    This research paper investigates the effects of the combination of the probiotic Lactobacillus plantarum F3-2 with the prebiotic mannan oligosaccharide (MOS) on obese mice and analyses the underlying mechanisms.

    Study Objectives
    • To assess the effect of combined probiotic and prebiotic intervention on obesity.
    • To investigate the mechanism of the combined action.
    Research Methods
    • Mice were divided into four groups: control group, high-fat diet group, MOS intervention group, and F3-2+MOS combined intervention group.
    • After 6 weeks of intervention, body weight, adipose tissue weight, serum lipid level, adipocyte size, expression of key genes of lipid metabolism, and fecal levels of short-chain fatty acids (SCFAs) were measured.
    Study Results
    • Body weight and adipose tissue: The body weight, adipose tissue weight and adipocyte size of mice in the F3-2+MOS combined intervention group were significantly lower than those in the MOS alone intervention group, suggesting that the combined intervention was more effective in suppressing fat accumulation.
    • Lipid levels: Serum triglyceride levels were significantly reduced after MOS intervention, while triglyceride levels were further reduced in the F3-2+MOS combined intervention group, suggesting that the combined intervention was more effective in improving lipid levels.
    • Levels of SCFAs: Concentrations of acetic acid, propionic acid and butyric acid in faeces were significantly increased after MOS intervention, whereas the concentrations of these three SCFAs were further increased in the F3-2+MOS combined intervention group, especially the concentration of butyric acid was significantly increased.
    • Expression of key genes for lipid metabolism: PPARγ and C/EBPα gene expression was significantly down-regulated in the adipose tissue of mice in the F3-2+MOS co-intervention group, suggesting that the co-intervention was more effective in inhibiting adipocyte differentiation.
    Study Conclusion
    • F3-2+MOS combined intervention can effectively improve obesity, and its mechanism may be through elevating the level of SCFAs, especially butyric acid, in feces, and then inhibiting the expression of key genes of lipid metabolism in adipose tissues, inhibiting adipocyte differentiation, and ultimately achieving the effect of reducing body weight and improving the level of blood lipids.
    Research Implications
    • Provides a new strategy for dietary intervention for obesity, i.e. the use of synbiotic products.
    • Provides a theoretical basis for the development of novel weight loss products, such as probiotic drinks or foods containing F3-2 and MOS.
    Research Outlook
    • To explore in depth how F3-2 affects the level of SCFAs and other mechanisms of action.
    • Evaluate the effects of F3-2+MOS on human obesity.
    Summary

    This study demonstrates the effectiveness of combined probiotic and prebiotic interventions in obesity and reveals the underlying mechanisms. This provides a theoretical basis for the development of novel weight loss products and new ideas for dietary intervention in obesity.

    Frequently Asked Questions

    What is the patent number for Lactiplantibacillus plantarum F3-2?

    The patent number is ZL202110850565.9, which covers "A strain of lactiplantibacillus plantarum F3-2 and its application".

    What are the primary applications of this strain?

    Lactiplantibacillus plantarum F3-2 can be applied in Dairy, Food, Fermented Beverages, Pharmaceuticals, Biotechnology, and Feed Additives/Pet products.

    What customized potencies are available?

    We accept customized product requests with potency concentrations including 10B CFU/g, 50B CFU/g, 100B CFU/g, 200B CFU/g, 300B CFU/g, 400B CFU/g, and 500B CFU/g.

    What are the storage requirements and shelf life?

    The product should be stored at -18℃ or below, and it has a shelf life of 24 months under these storage conditions.

    How does Lactiplantibacillus plantarum F3-2 combined with MOS help with obesity?

    Academic research shows that the combined intervention of F3-2 and mannan oligosaccharide (MOS) elevates fecal short-chain fatty acids (SCFAs), particularly butyric acid. This inhibits PPARγ and C/EBPα gene expression, suppressing adipocyte differentiation and fat accumulation.

    Leave Your Message